Teva and Active Biotech Remain Committed to the Development of NERVENTRA® (laquinimod) for Multiple Sclerosis Following the Negative Opinion from the EMA's CHMP

| Source: Active Biotech AB
JERUSALEM, Israel & LUND, Sweden, January 24, 2014 - Teva Pharmaceutical
Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI)
announced today that both companies remain committed to the NERVENTRA(®)
(laquinimod) clinical development program for multiple sclerosis (MS) following
the announcement of a negative opinion for the treatment of relapsing-remitting
multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA).

The CHMP has concluded that the risk-benefit profile of NERVENTRA is not
favorable at this time. In accordance with European regulations, Teva and Active
Biotech intend to request a re-examination of the CHMP opinion. Teva and Active
Biotech are focusing on evaluating the CHMP's review and will continue to liaise
closely with the EMA in working to make NERVENTRA available as a new treatment
option for patients with RRMS in Europe.

NERVENTRA is a once-daily oral, investigational, CNS-active immunomodulator with
a novel mechanism of action being developed for the treatment of relapsing-
remitting MS (RRMS) and progressive MS (PMS). In extensive non-clinical and
clinical studies NERVENTRA has demonstrated both anti-inflammatory and
neuroprotective properties and effects that have been shown to provide
clinically meaningful results. The global Phase III clinical development program
evaluating NERVENTRA in MS includes two pivotal studies, ALLEGRO and BRAVO. A
third Phase III NERVENTRA trial, CONCERTO, is evaluating two doses of the
investigational product (0.6mg and 1.2mg) in approximately 1,800 patients for up
to 24 months. The primary outcome measure will be time to confirmed disability
progression as measured by the EDSS.

The safety profile of NERVENTRA is based on 2645 MS patients that have been
exposed to NERVENTRA for a total duration of 7490.8 subject years, with a
maximal duration of seven years. Very common or important adverse reactions
include headache, abdominal pain, back and neck pain, appendicitis, and mild,
asymptomatic laboratory abnormalities, including liver enzyme elevations,
hematological changes, and elevation of CRP or fibrinogen levels. Potential
risks include teratogenicity and carcinogenicity, both related to findings in
rats, which are based on non-clinical data and have not been encountered in

In addition to the MS clinical studies, NERVENTRA is currently in clinical
development for Crohn's disease. Studies are also planned to study the efficacy,
safety and tolerability of NERVENTRA in other neurodegenerative diseases,
including Huntington's disease.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's leading generic drug
maker, with a global product portfolio of more than 1,000 molecules and a direct
presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $20.3 billion in net revenues in 2012.

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is
laquinimod, an orally administered small molecule with unique immunomodulatory
properties for the treatment of multiple sclerosis. Also tasquinimod for the
treatment of prostate cancer, with a unique mode of action, is in pivotal phase.
In addition, laquinimod has concluded Phase II development for Crohn's and
Lupus. The company has two additional projects in clinical development, ANYARA
primarily for the treatment of renal cell cancer and the orally administered
compound paquinimod (57-57) for systemic sclerosis. Please visit for more information.

Teva's  Safe  Harbor  Statement  under  the  U. S. Private Securities Litigation
Reform   Act   of  1995: The  following  presentation  contains  forward-looking
statements,  which express the  current beliefs and  expectations of management.
Such  statements involve a  number of known  and unknown risks and uncertainties
that  could  cause  our  future  results,  performance or achievements to differ
significantly from the results, performance or achievements expressed or implied
by  such  forward-looking  statements.  Important  factors  that  could cause or
contribute to such differences include risks relating to: our ability to develop
and  commercialize  additional  pharmaceutical  products,  competition  for  our
innovative   medicines,   especially  Copaxone(®)  (including  competition  from
innovative orally-administered alternatives, as well as from potential purported
generic equivalents), competition for our generic products (including from other
pharmaceutical  companies  and  as  a  result  of increased governmental pricing
pressures), competition for our specialty pharmaceutical businesses, our ability
to  achieve expected  results through  our specialty,  including innovative, R&D
efforts,  the effectiveness of our patents  and other protections for innovative
products,  decreasing  opportunities  to  obtain  U.S.  market  exclusivity  for
significant  new  generic  products,  our  ability  to  identify, consummate and
successfully  integrate acquisitions and license products, our ability to reduce
operating  expenses to the extent and during  the timeframe intended by our cost
restructuring   program,  uncertainties  relating  to  the  replacement  of  and
transition  to  a  new  President  &  Chief  Executive  Officer,  the effects of
increased  leverage as a result of recent  acquisitions, the extent to which any
manufacturing or quality control problems damage our reputation for high quality
production  and require  costly remediation,  our potential  exposure to product
liability  claims to the  extent not covered  by insurance, increased government
scrutiny  in both the  U.S. and Europe  of our settlement  agreements with brand
companiesand  liabilities arising from class  action litigation and other third-
party  claims  relating  to  such  agreements,  potential liability for sales of
generic  medicines prior to a final resolution of outstanding patent litigation,
our  exposure to currency fluctuations and restrictions as well as credit risks,
the  effects of reforms in healthcare  regulation and pharmaceutical pricing and
reimbursement,  any  failures  to  comply  with  complex  Medicare  and Medicaid
reporting  and payment  obligations, governmental  investigations into sales and
marketing  practices ,particularly for our  specialty medicines (and our ongoing
FCPA   investigations   and  related  matters),  uncertainties  surrounding  the
legislative  and  regulatory  pathways  for  the  registration  and  approval of
biotechnology-based   medicines,   adverse  effects  of  political  or  economic
instability,   corruption,  major  hostilities  or  acts  of  terrorism  on  our
significant  worldwide operations, interruptions in our supply chain or problems
with  our  information  technology  systems  that  adversely  affect our complex
manufacturing  processes,  any  failure  to  retain  key personnel or to attract
additional   executive   and   managerial   talent,  the  impact  of  continuing
consolidation  of our distributors and customers, variations in patent laws that
may  adversely  affect  our  ability  to  manufacture  our  products in the most
efficient  manner, potentially significant impairments  of intangible assets and
goodwill,  potential increases in  tax liabilities resulting  from challenges to
our  intercompany arrangements,  the termination  or expiration  of governmental
programs  or  tax  benefits,  environmental  risks,  and  other factors that are
discussed  in  our  Annual  Report  on  Form  20-F  for  the year ended December
31, 2012 and  in  our  other  filings  with  the  U.S.  Securities  and Exchange
Commission.  Forward-looking statements speak only as  of the date on which they
are  made  and  the  Company  undertakes  no  obligation to update or revise any
forward looking statement, whether as a result of new information, future events
or otherwise.

Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act:
This press release contains certain forward-looking statements. Such forward-
looking statements involve known and unknown risks, uncertainties and other
important factors that could cause the actual results, performance or
achievements of the company, or industry results, to differ materially from any
future results, performance or achievement implied by the forward-looking
statements. The company does not undertake any obligation to update or publicly
release any revisions to forward-looking statements to reflect events,
circumstances or changes in expectations after the date of this press release.

Active  Biotech is obligated to publish  the information contained in this press
release  in accordance with  the Swedish Securities  Market Act.This information
was provided to the media for publication 1:05 p.m. CET on January 24, 2014.